• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. 
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    •   QMRO Home
    • Wolfson Institute of Preventive Medicine
    • Centre for Cancer Prevention
    • What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.

    View/Open
    Accepted version (83.07Kb)
    Accepted version (Supplementary material) (21.58Kb)
    Accepted version (Supplementary tables) (463.1Kb)
    Accepted version (Figure 1) (228.7Kb)
    Accepted version (Figure 2) (45.83Kb)
    Volume
    142
    Pagination
    709 - 718
    DOI
    10.1002/ijc.31094
    Journal
    Int J Cancer
    Issue
    4
    Metadata
    Show full item record
    Abstract
    Women vaccinated against HPV16/18 are approaching the age for cervical screening; however, an updated screening algorithm has not been agreed. We use a microsimulation model calibrated to real published data to determine the appropriate screening intensity for vaccinated women. Natural histories in the absence of vaccination were simulated for 300,000 women using 10,000 sets of transition probabilities. Vaccination with (i) 100% efficacy against HPV16/18, (ii) 15% cross-protection, (iii) 22% cross-protection, (iv) waning vaccine efficacy and (v) 100% efficacy against HPV16/18/31/33/45/52/58 was added, as were a range of screening scenarios appropriate to the UK. To benchmark cost-benefits of screening for vaccinated women, we evaluated the proportion of cancers prevented per additional screen (incremental benefit) of current cytology and likely HPV screening scenarios in unvaccinated women. Slightly more cancers are prevented through vaccination with no screening (70.3%, 95% CR: 65.1-75.5) than realistic compliance to the current UK screening programme in the absence of vaccination (64.3%, 95% CR: 61.3-66.8). In unvaccinated women, when switching to HPV primary testing, there is no loss in effectiveness when doubling the screening interval. Benchmarking supports screening scenarios with incremental benefits of ≥2.0%, and rejects scenarios with incremental benefits ≤0.9%. In HPV16/18-vaccinated women, the incremental benefit of offering a third lifetime screen was at most 3.3% (95% CR: 2.2-4.5), with an incremental benefit of 1.3% (-0.3-2.8) for a fourth screen. For HPV16/18/31/33/45/52/58-vaccinated women, two lifetime screens are supported. It is important to know women's vaccination status; in these simulations, HPV16/18-vaccinated women require three lifetime screens, HPV16/18/31/33/45/52/58-vaccinated women require two lifetime screens, yet unvaccinated women require seven lifetime screens.
    Authors
    Landy, R; Windridge, P; Gillman, MS; Sasieni, PD
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/36725
    Collections
    • Centre for Cancer Prevention [227]
    Language
    eng
    Licence information
    This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
    Copyright statements
    © 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.